191 related articles for article (PubMed ID: 33647675)
1. Anti-protozoal activity of Thymol and a Thymol ester against Cryptosporidium parvum in cell culture.
Dominguez-Uscanga A; Aycart DF; Li K; Witola WH; Andrade Laborde JE
Int J Parasitol Drugs Drug Resist; 2021 Apr; 15():126-133. PubMed ID: 33647675
[TBL] [Abstract][Full Text] [Related]
2. Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum.
Li K; Grooms GM; Khan SM; Hernandez AG; Witola WH; Stec J
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():80-90. PubMed ID: 33011650
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.
Nava MG; Calderón F; Fernández E; Ballell L; Bamborough P; Vinayak S
Microbiol Spectr; 2023 Feb; 11(1):e0387422. PubMed ID: 36533912
[TBL] [Abstract][Full Text] [Related]
4. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
5. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target.
Yang B; Yan Y; Wang D; Zhang Y; Yin J; Zhu G
PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011217. PubMed ID: 36972284
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
7. Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against
Khan SM; Bajwa MR; Lahar RY; Witola WH
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0056923. PubMed ID: 37655889
[No Abstract] [Full Text] [Related]
8. Mass Spectrometry Imaging of In Vitro
Anschütz NH; Gerbig S; Ghezellou P; Silva LMR; Vélez JD; Hermosilla CR; Taubert A; Spengler B
Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627264
[No Abstract] [Full Text] [Related]
9. Host cells with transient overexpression of MDR1 as a novel in vitro model for evaluating on-target effect for activity against the epicellular Cryptosporidium parasite.
Yang B; Wang D; Liu M; Wu X; Yin J; Zhu G
J Antimicrob Chemother; 2021 Dec; 77(1):124-134. PubMed ID: 34648615
[TBL] [Abstract][Full Text] [Related]
10. Anti-protozoal activity of extracts from chicory (Cichorium intybus) against Cryptosporidium parvum in cell culture.
Woolsey ID; Valente AH; Williams AR; Thamsborg SM; Simonsen HT; Enemark HL
Sci Rep; 2019 Dec; 9(1):20414. PubMed ID: 31892721
[TBL] [Abstract][Full Text] [Related]
11. Systemic efficacy on
Diawara EH; François A; Stachulski AV; Razakandrainibe R; Costa D; Favennec L; Rossignol JF; Gargala G
Parasitology; 2021 Jul; 148(8):975-984. PubMed ID: 33775260
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.
Guo F; Zhang H; Fritzler JM; Rider SD; Xiang L; McNair NN; Mead JR; Zhu G
J Infect Dis; 2014 Apr; 209(8):1279-87. PubMed ID: 24273180
[TBL] [Abstract][Full Text] [Related]
13. Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin.
Ma J; Guo F; Jin Z; Geng M; Ju M; Ravichandran A; Orugunty R; Smith L; Zhu G; Zhang H
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457108
[TBL] [Abstract][Full Text] [Related]
14. Neonatal Mouse Gut Metabolites Influence Cryptosporidium parvum Infection in Intestinal Epithelial Cells.
VanDussen KL; Funkhouser-Jones LJ; Akey ME; Schaefer DA; Ackman K; Riggs MW; Stappenbeck TS; Sibley LD
mBio; 2020 Dec; 11(6):. PubMed ID: 33323514
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ginsenoside-Rh2 and Curcurbitacin-B on Cryptosporidium parvum in vitro.
Shahiduzzaman M; Ras R; Widmer G
Exp Parasitol; 2020 May; 212():107873. PubMed ID: 32165146
[TBL] [Abstract][Full Text] [Related]
16. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
[TBL] [Abstract][Full Text] [Related]
17. A novel, stain-free, natural auto-fluorescent signal, Sig M, identified from cytometric and transcriptomic analysis of infectivity of
Ogbuigwe P; Roberts JM; Knox MA; Heiser A; Pita A; Haack NA; Garcia-Ramirez JC; Velathanthiri N; Biggs PJ; French NP; Hayman DTS
Front Cell Infect Microbiol; 2023; 13():1178576. PubMed ID: 37284498
[TBL] [Abstract][Full Text] [Related]
18. Effect of oregano essential oil and carvacrol on Cryptosporidium parvum infectivity in HCT-8 cells.
Gaur S; Kuhlenschmidt TB; Kuhlenschmidt MS; Andrade JE
Parasitol Int; 2018 Apr; 67(2):170-175. PubMed ID: 29155281
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory activity of chitosan nanoparticles against Cryptosporidium parvum oocysts.
Ahmed SA; El-Mahallawy HS; Karanis P
Parasitol Res; 2019 Jul; 118(7):2053-2063. PubMed ID: 31187224
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteins and Gal-GalNAc cause Cryptosporidium to switch from an invasive sporozoite to a replicative trophozoite.
Edwinson A; Widmer G; McEvoy J
Int J Parasitol; 2016 Jan; 46(1):67-74. PubMed ID: 26432292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
